Compare Adecoagro SA (AGRO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs State Street SPDR S&P Biotech ETF — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.36B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Adecoagro SA pays a 3.15% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Adecoagro SA nearer its low. Which is the better fit depends on your goals.
| AGRO | XBI | |
|---|---|---|
Market Cap | $1.36B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $15.25 | $164.28 |
52-Week Low | $7.13 | $86.92 |
Enterprise Value | $3.39B | — |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.29, down 3.83% today, with a bearish technical signal and mixed earnings performance. The company reported strong adjusted EBITDA growth in Q2 2026 ($172.5M) and is expanding via acquisition of the Caarapó mill. However, recent quarters show earnings misses against expectations, with net income margin at just 0.91% for 2026. Valuation metrics appear reasonable with P/S of 0.71 and P/B of 0.77, but high P/E of 522.78 reflects profitability challenges.
The outlook remains cautious with analyst consensus leaning toward Hold (50%) amid execution risks from recent acquisitions and commodity volatility. Positive catalysts include operational efficiency gains and expansion in South American markets, but investors face headwinds from elevated leverage and macroeconomic sensitivity to oil and gas prices.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
